Join
Live feed
·
INSIDERFilingvia Quantisnow
Kairos Pharma Ltd. logo

VP of Research and Development Murali Ramachandran was granted 14,000 shares, increasing direct ownership by 11% to 147,057 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
KAPA· Kairos Pharma Ltd.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KAPA (Kairos Pharma Ltd.) and more on Quantisnow.